Key Insights

Highlights

Success Rate

79% trial completion

Published Results

52 trials with published results (46%)

Research Maturity

71 completed trials (63% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

16.8%

19 terminated out of 113 trials

Success Rate

78.9%

-7.6% vs benchmark

Late-Stage Pipeline

8%

9 trials in Phase 3/4

Results Transparency

73%

52 of 71 completed with results

Key Signals

52 with results79% success19 terminated

Data Visualizations

Phase Distribution

109Total
Not Applicable (16)
Early P 1 (2)
P 1 (25)
P 2 (57)
P 3 (9)

Trial Status

Completed71
Terminated19
Unknown10
Active Not Recruiting8
Withdrawn4
Recruiting1

Trial Success Rate

78.9%

Benchmark: 86.5%

Based on 71 completed trials

Clinical Trials (113)

Showing 20 of 20 trials
NCT02296229Not ApplicableActive Not RecruitingPrimary

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

NCT01517451Phase 1CompletedPrimary

Radiation and Androgen Ablation for Prostate Cancer

NCT03624660Phase 2Active Not RecruitingPrimary

Dose-Escalated Proton Radiation Therapy for High-Risk Prostate Cancer

NCT03511196Early Phase 1Active Not Recruiting

Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer

NCT02023463Phase 1Active Not RecruitingPrimary

Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prostate Cancer

NCT02203695Phase 2CompletedPrimary

Randomized Salvage Radiation Therapy Plus Enzalutamide Post Prostatectomy

NCT01655836Phase 1Active Not Recruiting

High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer

NCT03432897Phase 2Terminated

BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes

NCT02278185Phase 2CompletedPrimary

Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer

NCT01848067Phase 1CompletedPrimary

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

NCT03689699Phase 1Active Not Recruiting

Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8)

NCT02176902Not ApplicableActive Not RecruitingPrimary

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

NCT01255891Phase 2CompletedPrimary

Adjuvant Androgen Suppression Plus Radiation Therapy for High-Risk Localized Adenocarcinoma Prostate

NCT03686683Phase 3CompletedPrimary

Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

NCT02184533Phase 1CompletedPrimary

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

NCT04694924Recruiting

Prospective Prostate Cancer and Patient-reported Outcomes Registry

NCT02163317Not ApplicableCompletedPrimary

Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer

NCT00019695Phase 2Terminated

Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer

NCT04909294Not ApplicableActive Not RecruitingPrimary

Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma

NCT01697384Phase 3Completed

Study to Evaluate Efficacy and Safety of Histrelin Subdermal Implant in Men With Advanced Prostate Cancer

Scroll to load more

Research Network

Activity Timeline